ABUS (Arbutus Biopharma) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


ABUS Arbutus Biopharma Corp ABUS
53 GF Score
Price $4.33
GF Value $51.42
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Arbutus Biopharma's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ABUS vs SPRY, KURA, JANX: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Arbutus Biopharma's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arbutus Biopharma Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Margin of Safety % (DCF FCF Based) falls into.


ABUS
53GF Score
Arbutus Biopharma Corp ABUS
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $4.33 is trading 91.6% below its estimated GF Value™ of $51.42. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $51.42 vs. price of $4.33 (91.6% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score

Get the complete analysis for ABUS

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.33
Price
$51.42
GF Value